ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

ARS Pharma SPRY Q3 2025 Earnings Call Transcript

ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion.

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.

ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.

FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.